Rhabdomyolysis (RM) is characterized by acute and often severe skeletal muscle damage resulting in myoglobinuria and, in severe cases, acute renal failure \[[@bb0005]\]. In adults is typically due to trauma, intoxication or infection, whereas in children is frequently associated with inherited muscle disorders \[[@bb0010]\]. *LPIN1* mutations were identified as a cause of severe recurrent RM, which usually begin in childhood, and infections are the most frequent trigger \[[@bb0015], [@bb0020]\]. *LPIN1* spans 19 exons and encodes lipin-1, an 890 amino acid protein predominantly expressed in skeletal muscle and adipose tissue, which accounts for phosphatidic acid phosphatase activity \[[@bb0010], [@bb0025]\]. To date, 36 *LPIN1* mutations have been described related with RM ([Fig. 1](#f0005){ref-type="fig"}a).

We report a 35-year-old female patient presenting myalgia, muscle weakness, general fatigue and sleep apnea. Her first child born from an apparently non-consanguineous marriage (father already dead), presented normal growth and psychomotor development until the age of 2 years, when developed recurrent RM events precipitated by infections, without symptoms and normal plasma creatine kinase between episodes. The child died at 4-year-old due to a crisis of RM during gastroenteritis. A novel *LPIN1* splicing mutation (c.2142-2 A \> G) was identified in heterozygous state, in the index case, however, her child was homozygous ([Fig. 1](#f0005){ref-type="fig"}b). This novel mutation is probably pathogenic, predicted by bioinformatics tools, due to the break of acceptor site which affect the splicing mechanisms \[[@bb0030], [@bb0035]\].

*LPIN1* mutations appear as the second most common cause of early-onset RM, after primary fatty acid oxidation defects as a whole \[[@bb0040]\]. Heterozygous *LPIN1* mutations may also produce symptoms of cramps and exercise-induced myalgia or mild muscular symptoms \[[@bb0010]\], as occurred in our family.

This study allowed the identification of the first *LPIN1* mutation in Portuguese patients and corroborates the importance of a molecular testing to confirm *LPIN1* patients (children and adults) with recurrent RM.
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